About Sialic acid-binding Ig-like lectin 14
Sialic acid-binding Ig-like lectin 14 (SIGLEC14) is a protein
from Homo sapiens identified by UniProt accession
Q08ET2, 396 residues long.
MolForge cross-references it against 0 known binders and
106 disease associations.
Target properties
| Protein name | Sialic acid-binding Ig-like lectin 14 |
| UniProt accession | Q08ET2 |
| Gene | SIGLEC14 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (106)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.25
- calcium measurement · score 0.21
- sialic acid-binding Ig-like lectin 14 measurement · score 0.20
- Red cell distribution width · score 0.20
- pancreatic adenocarcinoma · score 0.18
- protein measurement · score 0.18
- basophil count · score 0.17
- plasma plasminogen measurement · score 0.12
- monocyte count · score 0.08
- platelet component distribution width · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q08ET2-F1 | alphafold | PREDICTED | 83.43 | — |
Amino-acid sequence (396 residues)
MLPLLLLPLL WGGSLQEKPV YELQVQKSVT VQEGLCVLVP CSFSYPWRSW YSSPPLYVYW FRDGEIPYYA EVVATNNPDR RVKPETQGRF RLLGDVQKKN CSLSIGDARM EDTGSYFFRV ERGRDVKYSY QQNKLNLEVT ALIEKPDIHF LEPLESGRPT RLSCSLPGSC EAGPPLTFSW TGNALSPLDP ETTRSSELTL TPRPEDHGTN LTCQVKRQGA QVTTERTVQL NVSYAPQNLA ISIFFRNGTG TALRILSNGM SVPIQEGQSL FLACTVDSNP PASLSWFREG KALNPSQTSM SGTLELPNIG AREGGEFTCR VQHPLGSQHL SFILSVQRSS SSCICVTEKQ QGSWPLVLTL IRGALMGAGF LLTYGLTWIY YTRCGGPQQS RAERPG
Explore Sialic acid-binding Ig-like lectin 14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets